What You Should Know:
- Deloitte Centre for Health Solutions releases its thirteenth annual report, ‘Seize the Digital Momentum: Measuring the return from pharmaceutical innovation 2022’ that explores the performance of the biopharmaceutical industry (bio Pharma) and its ability to generate returns from investment in innovative new medicines.
- Since 2021, much of the world has successfully adjusted to life where COVID-19 is more endemic as vaccines and treatments reduced the risk and
Read More
Clinical Trial
Faro Health Secures $20M to Streamline Smart Clinical Trials
What You Should Know:
- Faro Health, a cloud-computing company that is developing digital infrastructure for smart clinical trials raises $20M in Series A funding led by General Catalyst to help scale the digital transformation of clinical trials––essentially making it easier and quicker for drug developers to greatly reduce the cost and time of trials.
- The round also included participation from previous investors Section 32, Polaris Partners, Zetta Ventures, and Northpond Ventures.
Read More
Biden Admin Builds on Cancer Moonshot with 13 More Initiatives
What You Should Know:
- One year ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot, setting an ambitious, achievable goal: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and families living with and surviving cancer, ultimately ending cancer as we know it today.
- The Cancer Moonshot has spurred tremendous action across the federal government and from the public and private
Read More
Curebase Launches Remote First DTx Research Platform
What You Should Know:
- Curebase, a company committed to democratizing access to clinical trials, announced the release of its integrated software and services package for digital therapeutics (DTx) trials that accelerates enrollment and allows sponsors to launch their studies faster.
- Available now, the new Curebase offering includes the first one-stop-shop decentralized clinical trial (DCT) platform bundled with site and trial execution services for the DTx market.
Making
Read More
Healthcare AI Transformation: 9 Executive Predictions to Watch in 2023
Piotr Orzechowski, Co-Founder and CEO of Infermedica
Innovation areas to watch: One of the exciting areas of applied machine learning recently is so-called Generative Tech. Some say it’s the biggest change to the Internet since crypto was invented. Generative Tech is developing at an unprecedented pace and many of us already had a chance to enjoy images created by OpenAI’s DALLE-E or content generated by GPT-3 language model. However real-world applications of generative tech in health are
Read More
Boosting Clinical Trial Recruitment Requires Humanity – and Technology
Clinical trials should be a time of promise for better patient outcomes, as they explore new ways to potentially help patients suffering from a variety of conditions. Instead, this phase of treatment development is often met with exasperation as patients, researchers, and drug developers deal with the many barriers to clinical trial recruitment and access.
There are two central – and intrinsically linked – problems with the current state of clinical trial recruitment in the U.S.:
Read More
7 Life Sciences Executive Predictions to Watch in 2023
Tracy Curley, CFO and interim CEO at iSpecimen
Focusing on the macroeconomic environment, which remains impacted by the lingering COVID-19 pandemic, there continues to be uncertainty about the strength of the global, Asia Pacific, UK and US economies. High-interest rates and a potential recession remain a concern for all market participants. At ISPC, we are closely monitoring the pace of specimen transactions. We believe that this industry can be resilient through a continued economic
Read More
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
Real-World Study Uses AI to Identify Undiagnosed Dementia in Primary Care
What You Should Know:
- Rising to meet the formidable challenge of the timely diagnosis of dementia, research scientists from Regenstrief Institute, IUPUI and the medical schools of Indiana University and the University of Miami are conducting the Digital Detection of Dementia study, a real-world evaluation of the use of an artificial intelligence (AI) tool they developed for early identification of Alzheimer’s disease and related dementias in primary care, the setting where most adults
Read More
Biomica Raises $20M to Advance its Pipeline of Microbiome-based Therapeutics
What You Should Know:
- Biomica, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd raises $20M led by Shanghai Healthcare Capital (SHC).
- The financing round will enable Biomica to forge ahead, developing its pipeline of microbiome-based therapeutics. Biomica plans to use the proceeds to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial; scale up and complete GMP
Read More
